These previous clinical trials, based on the United States and Europe, show satisfying remission rates in response to lentivirally transduced CD19-CAR-T cells in R/R B-ALL patients, while these trials are based on white population in the United States and Europe, and their sample sizes are relatively small. Here, CD19 is linked to acute lymphoblastic leukemia.